4baseCare Raises $6 Million in Series A Funding to Advance Precision Oncology

Healthtech Startup Attracts Investment for Advanced Genomics and Digital Health

Mumbai, India – August 12, 2024

4baseCare, an Illumina Accelerator Company specializing in precision oncology through advanced genomics and digital health, has secured $6 million (around INR 50 Cr) in its Series A funding round led by Yali Capital. This funding will enable 4baseCare to further develop its technology platform, expand its team, and launch new products and services.

4baseCare's mission is to improve cancer patient outcomes by providing personalized treatment plans based on their unique genetic profiles. The company's platform integrates genomic data with clinical data and patient-reported outcomes to create a comprehensive view of each patient's cancer. This information is then used to develop individualized treatment plans that are tailored to the patient's specific needs.

4baseCare's Series A funding round was led by Yali Capital, a venture capital firm specializing in healthcare and technology investments. Other investors in the round included Illumina Ventures and Axilor Ventures. The funding will be used to accelerate the development of 4baseCare's technology platform, expand its team, and launch new products and services.

"We are excited to partner with Yali Capital, Illumina Ventures, and Axilor Ventures to bring precision oncology to more patients around the world," said Srikanth Krishnan, CEO of 4baseCare. "This funding will allow us to accelerate the development of our technology platform, expand our team, and launch new products and services that will improve cancer patient outcomes."